XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Total revenue $ 334,617 $ 978,052
Costs and expenses:    
Costs of research and development revenue 143,955 726,918
Research and development 522,723 810,566
General and administrative 1,788,594 1,480,040
Foreign currency exchange loss 4,903 11,022
Total costs and expenses 2,460,175 3,028,546
Loss from operations (2,125,558) (2,050,494)
Other income (expense):    
Interest income 87,443 104,731
Gain on sale of Alphazyme 60,977 989,319
Total other income (expense), net 115,962 1,094,050
Net loss $ (2,009,596) $ (956,444)
Basic and diluted net loss per common share (in dollars per share) $ (0.07) $ (0.03)
Basic and diluted weighted-average common shares outstanding (in shares) 28,828,282 28,761,469
Nonrelated Party [Member]    
Other income (expense):    
Interest expense $ (21,639) $ 0
Related Party [Member]    
Other income (expense):    
Interest expense (10,819) 0
Research and Development [Member]    
Revenues:    
Total revenue 334,617 933,934
License [Member]    
Revenues:    
Total revenue $ 0 $ 44,118